-
公开(公告)号:WO2010104406A1
公开(公告)日:2010-09-16
申请号:PCT/NZ2010000040
申请日:2010-03-11
申请人: AUCKLAND UNISERVICES LTD , SMAILL JEFFREY BRUCE , PATTERSON ADAM VORN , DENNY WILLIAM ALEXANDER , WILSON WILLIAM ROBERT , LU GUO-LIANG , ANDERSON ROBERT FORBES , LEE HO HUAT , ASHOORZADEN AMIR
发明人: SMAILL JEFFREY BRUCE , PATTERSON ADAM VORN , DENNY WILLIAM ALEXANDER , WILSON WILLIAM ROBERT , LU GUO-LIANG , ANDERSON ROBERT FORBES , LEE HO HUAT , ASHOORZADEN AMIR
IPC分类号: C07D471/04 , A61K31/4178 , A61K31/4709 , A61K31/517 , A61K31/519 , A61P35/00 , C07D239/94 , C07D403/12 , C07D403/14 , C07D405/14
CPC分类号: C07D471/04 , A61K31/4178 , A61K31/4709 , A61K31/517 , A61K31/519 , C07D239/94 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14
摘要: The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula -(CH2)nTr, where Tr is an aromatic nitroheterocycle or aromatic nitrocarbocycle and -(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3 and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.
摘要翻译: 本发明提供包含激酶抑制剂和还原活化的片段化芳族硝基杂环或芳族硝基碳环触发剂的新型前药化合物,其中化合物携带正电荷。 在优选的实施方案中,化合物具有式I:其中:X是任何带负电的抗衡离子; R1是式 - (CH2)nTr的基团,其中Tr是芳族硝基杂环或芳族硝基碳环,和 - (CH2)nTr作为还原活化的片段触发剂; n为0〜6的整数。 R2,R3和R4可以各自独立地选自叔胺激酶抑制剂(R2)(R3)(R4)N的脂族或芳族基团,或者R2,R3和R4中的两个可以形成脂族或芳族杂环胺环 的激酶抑制剂,或R 2,R 3和R 4中的一个可以不存在,R2,R3和R4中的两个形成激酶抑制剂的芳族杂环胺环。 本发明的化合物可用于治疗增殖性疾病如癌症。